Company Overview and News

 
Renegade Exploration revs up for major drilling program in premier gold country

2018-05-21 proactiveinvestors.com.au
Renegade Exploration Ltd (ASX:RNX) will get the drill bit spinning in early June targeting gold at its Yandal East project in the gold-rich Yandal Greenstone Belt of Western Australia.

 
Renegade Exploration leveraged to gold news flow from world-class Yandal Greenstone Belt

2018-05-10 proactiveinvestors.com.au
Renegade Exploration Ltd (ASX:RNX) is focused on finding another major gold project in the elephant country that is the Yandal Greenstone Belt near Wiluna in Western Australia’s North Eastern Goldfields.

 
Renegade Exploration to drill for gold near 10 million ounce Jundee project

2018-05-04 proactiveinvestors.com.au
Renegade Exploration Ltd (ASX:RNX) started trading on the ASX today after changing its name from Overland Resources Ltd (ASX:OVR).

 
Loosen up men and cut old boardroom ties

2017-06-18 smh.com.au
A few years ago, the then boss of Australia's largest rail freight network, Lance Hockridge, was riding a lift, when a group of female employees stepped in.

 
Storage group outlays $17m on WA properties

2017-04-20 businessnews.com.au
National Storage REIT intends to acquire two properties in Perth for a combined $17 million while confirming plans to develop two further sites, believed to be at Yanchep and Martin.

 
Stocks pare losses at noon

2016-05-31 at.theaustralian.com.au
The Australian sharemarket has pared losses at noon, after a stronger-than-expected building approvals update put a floor under selling.

 
 
 
NSR Expands to Central Coast

2016-04-14 asx.com.au

 
 
 
Appendix 3B

2016-02-29 asx.com.au

 

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

13h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

13h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...